Literature DB >> 9354427

Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

P L Dahia1, D J Marsh, Z Zheng, J Zedenius, P Komminoth, T Frisk, G Wallin, R Parsons, M Longy, C Larsson, C Eng.   

Abstract

The majority of familial medullary thyroid neoplasms are associated with germ-line mutations of the RET proto-oncogene, yet very little is known about the mechanisms involved in the pathogenesis of familial and sporadic nonmedullary thyroid tumors. A subset of thyroid tumors have loss of heterozygosity of chromosome 10q22-23, a region harboring the gene responsible for Cowden disease, an autosomal dominant hamartoma syndrome associated with thyroid and breast tumors. PTEN/MMAC1/TEP1 codes for a dual-specificity phosphatase and is likely a tumor suppressor gene. We sought to determine the PTEN status in a series of epithelial thyroid neoplasms. We studied 95 sporadic thyroid tumors, of which 39 were papillary thyroid carcinomas (PTCs), 12 were follicular carcinomas, 9 were anaplastic carcinomas, 5 were Hürthle cell carcinomas, 21 were nonfunctioning follicular adenomas, and 9 were Hürthle cell adenomas. Direct sequencing of PCR-amplified products was performed for all nine exons of PTEN. Two polymorphic markers, one located in intron 8 and another, a dinucleotide repeat marker, AFMa086wg9, located within intron 2, were analyzed in paired blood-tumor DNA samples to assess hemizygous deletions of PTEN. We found a somatic frameshift mutation in one PTC, which was expected to generate a premature stop codon 2 amino acids downstream. Twenty-six % of informative benign tumors (four follicular adenomas and three Hürthle cell adenomas) and only 3 of 49 (6.1%) informative malignant tumors (one PTC, one follicular carcinoma, and one anaplastic carcinoma) showed evidence of hemizygous deletion of PTEN (P = 0.046). We conclude that a subset of thyroid tumors have somatic deletions of the PTEN gene, predominantly the benign forms, and that small intragenic mutations of PTEN are infrequent in thyroid tumors. We speculate that other mechanisms of PTEN inactivation, rather than small intragenic mutations, might occur in the hemizygously deleted samples and act as the "Knudson second hit." Alternatively, other tumor suppressor genes mapping to chromosome 10q22-23 could be the actual targets for such deletions and thus represent the various hits in the pathway of multistep carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  Polymorphisms in PTEN in breast cancer families.

Authors:  B T Carroll; F J Couch; T R Rebbeck; B L Weber
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

Review 4.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

5.  Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair.

Authors:  J-P Lai; J T Dalton; D L Knoell
Journal:  Br J Pharmacol       Date:  2007-10-08       Impact factor: 8.739

6.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Authors:  Maria Letizia Motti; Daniela Califano; Giancarlo Troncone; Carmela De Marco; Ilenia Migliaccio; Emiliano Palmieri; Luciano Pezzullo; Lucio Palombini; Alfredo Fusco; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 8.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

9.  Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes.

Authors:  Z J Wang; F Taylor; M Churchman; G Norbury; I Tomlinson
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.